Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)
This is a single arm, open-label phase II study to evaluate the efficacy and safety of Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with potentially resectable liver metastasis from colorectal cancer.
Potentially Resectable Liver Metastasis From CRC|Colorectal Cancer
DRUG: Capecitabine plus oxaliplatin
To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer, 3.6 years
To investigate the response rate, 3.6 years|To evaluate the R0 resection rate, 3.6 years|To evaluate the safety profile of XELOX peri-operative treatment, 3.6 years
To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer